OSI Systems, Inc. — Form 10-Q Summary
Reporting period: The filing covers the three and nine months ended March 31, 2020, representing fiscal third quarter 2020. The requested “2019 Q3” appears to refer to the comparable prior-year quarter ended March 31, 2019. Financial statements are unaudited and amounts are generally in millions, except per-share data.
Business Context
OSI Systems designs and manufactures specialized electronic systems and components for security and inspection, healthcare, aerospace, defense and other markets. Its operating divisions are Security, Healthcare, and Optoelectronics and Manufacturing.
Key Financial Metrics
| Metric | Q3 FY2020 | Q3 FY2019 | Change |
|---|---|---|---|
| Net revenues | $292.9 million | $304.3 million | (4%) |
| Gross profit | $109.1 million | $111.3 million | (2%) |
| Gross margin | 37.3% | 36.6% | +70 bps |
| Income from operations | $23.6 million | $32.1 million | (26%) |
| Net income | $19.6 million | $19.6 million | Approximately flat |
| Diluted EPS | $1.06 | $1.05 | +1% |
Nine-month results: Revenue increased 2% to $889.1 million; gross profit increased slightly to $319.1 million, while gross margin declined to 35.9% from 36.3%. Operating income increased 2% to $81.4 million, net income increased 27% to $61.3 million, and diluted EPS increased to $3.28 from $2.58.
- Q3 segment revenue: Security $187.1 million, down 3%; Healthcare $45.7 million, down 7%; Optoelectronics and Manufacturing $60.1 million, down 3%.
- Nine-month segment revenue: Security $578.5 million, up 5%; Healthcare $127.9 million, down 8%; Optoelectronics and Manufacturing $182.7 million, approximately flat.
- Operating expenses: Q3 operating expenses rose to $85.5 million from $79.2 million, primarily because of $4.5 million of impairment, restructuring and other charges versus a $1.8 million benefit in the prior-year quarter. R&D increased 12% to $15.4 million, while SG&A declined 3% to $65.6 million.
- Taxes: Q3 included a $0.6 million tax benefit and a negative 3.4% effective tax rate, primarily reflecting a $5.1 million discrete return-to-provision tax benefit. Excluding discrete items, the Q3 effective tax rate was 23.7% versus 28.6% in the prior-year period.
- Cash flow: Nine-month operating cash flow was $105.6 million versus $87.7 million. Investing cash use was $28.3 million, including $16.1 million of capital expenditures. Financing cash use was $68.5 million, including $51.8 million of share repurchases and $26.8 million of tax payments related to equity awards.
- Cash and liquidity: Cash and cash equivalents were $101.0 million at March 31, 2020, up from $96.3 million at June 30, 2019. Approximately 64% of cash was held by foreign subsidiaries and may be subject to repatriation tax considerations.
- Debt: The company had $95.0 million outstanding under its $535 million revolving credit facility, $48.1 million of outstanding letters of credit, and $287.5 million principal amount of 1.25% convertible senior notes due September 2022. Revolving-facility availability was $391.9 million, and the company was in compliance with all covenants.
- Balance sheet: Total assets were $1.287 billion and total liabilities were $734.3 million at March 31, 2020. Accounts receivable rose to $257.5 million from $238.4 million, while inventories declined to $241.3 million from $273.7 million.
Material Changes Versus the Prior Comparable Period
- Q3 revenue declined because of lower Security cargo and vehicle inspection and explosive detection revenue, lower Healthcare patient-monitoring revenue, and lower Optoelectronics and Manufacturing contract-manufacturing revenue.
- COVID-19 adversely affected Security and Optoelectronics and Manufacturing revenue toward the end of the quarter. Healthcare experienced increased near-term demand for patient-monitoring products.
- Q3 operating income declined materially because the prior-year period benefited from legal-cost insurance recoveries, while the current period included a $3.3 million Healthcare product-line impairment and additional restructuring charges.
- Nine-month net income benefited from higher operating income, lower interest expense, and substantially lower income-tax expense, including $12.0 million of discrete tax benefits.
- The company repurchased 562,707 shares for $51.8 million during the nine months and completed its prior 1 million-share authorization. A new authorization for up to 1 million shares was approved in April 2020.
- The company adopted ASC 842 lease accounting on July 1, 2019, recording $26.4 million of operating lease liabilities and a corresponding right-of-use asset at March 31, 2020; management stated that adoption did not materially affect operating results or cash flow.
Outlook, Risks and Unusual Items
- COVID-19: Management expects continued uncertainty, supply-chain and logistics disruption, facility-utilization constraints, delayed orders and deliveries, and possible customer payment or contract delays. The potential financial impact of a prolonged pandemic could not be reasonably estimated and may be material.
- Mexican government contract: The turnkey security-screening contract was scheduled to expire in May 2020. Renewal discussions were ongoing, but no assurance was provided regarding continuation or terms.
- Legal and regulatory matters: The company faces consolidated securities class actions, shareholder derivative litigation, and ongoing SEC and DOJ investigations related to securities trading and matters associated with prior FCPA allegations. Outcomes, penalties and losses cannot currently be predicted or estimated; no loss accrual was recorded for these matters.
- Environmental contingency: The company continues investigating historical soil and groundwater contamination at its Hawthorne, California facility. No liability was accrued because an adverse loss was not considered probable and reasonably estimable, but a material adverse resolution remains possible.
- Other unusual items: The Healthcare division abandoned a non-core product line, resulting in a $3.3 million asset impairment. Acquisition-related contingent consideration had a fair value of $13.2 million at March 31, 2020, with a remaining maximum potential payment of $23.7 million under capped arrangements.
- Guidance: The filing does not provide formal revenue or earnings guidance. Management stated that available cash, operating cash flow and credit facilities were expected to fund operational needs for the next 12 months and foreseeable future, subject to pandemic-related uncertainties.
Investor Verification Checklist
- Verify the extent to which COVID-19 affected fourth-quarter demand, production capacity, backlog conversion, customer collections and margins.
- Verify whether the Mexican government contract was renewed, modified or terminated and assess the related revenue and cash-flow implications.
- Review subsequent developments in the SEC, DOJ, securities litigation, derivative litigation and environmental matters.
- Separate recurring earnings from the $5.1 million Q3 discrete tax benefit and the $12.0 million nine-month discrete tax benefits.
- Monitor liquidity, covenant compliance, foreign cash accessibility, letters of credit and the September 2022 convertible-note maturity.
- Assess the effect of share repurchases on per-share results and capital allocation, including the new April 2020 authorization.
- Reconcile segment growth and margin trends, particularly the decline in Healthcare and the lower nine-month Security gross margin caused by product mix.